EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy

Erica V Lin, Betania Arce, Santiago Alvarez-Arango, Melanie C Dispenza

Journal of Allergy and Clinical Immunology · 2025-09 · 156 (3) · 568-578

DOI: 10.1016/j.jaci.2025.05.030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-09. Verfasst von Erica V Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Md. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Hypersensitivity. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, American Academy of Allergy Asthma and Immunology, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As an essential component of the FcεRI pathway, Bruton tyrosine kinase (BTK) has become a target for treating allergic diseases. Several proof-of-concept studies using early-generation compounds such as ibrutinib and acalabrutinib demonstrated the ability of short courses of BTK inhibitors (BTKis) to reduce skin test responses to allergens, suppress basophil activation responses, and even completely prevent reactivity to allergenic food ingestion in humans. While early-generation BTKis do not have acceptable adverse effect profiles for chronic administration for nononcologic indications, newer compounds in development have higher selectivity for BTK and fewer adverse effects. In particular, remibrutinib has demonstrated remarkable efficacy and safety with chronic administration for chronic spontaneous urticaria and is poised to become the first BTKi approved in the United States for use in the allergy space. This review summarizes work using BTKis to treat allergic disorders, emphasizing safety and practical considerations for clinicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsHypersensitivityHumansAnimalsPiperidinesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

AcalabrutinibBruton tyrosine kinaseanaphylaxischronic urticariafood allergy

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, humanPiperidinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.
  • Departments of Medicine and Pediatrics, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex.
  • Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: mdispen1@jhmi.edu.

Förderung

  • NIAID NIH HHS
  • American Academy of Allergy Asthma and Immunology
  • National Institutes of Health

Zitieren

APA

Lin, E. V., Arce, B., Alvarez-Arango, S., & Dispenza, M. C. (2025). Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. Journal of Allergy and Clinical Immunology, 156(3), 568-578. https://doi.org/10.1016/j.jaci.2025.05.030

Vancouver

Lin EV, Arce B, Alvarez-Arango S, Dispenza MC. Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. Journal of Allergy and Clinical Immunology. 2025;156(3):568-578. doi:10.1016/j.jaci.2025.05.030

BibTeX
@article{Lin2025,
  author = {Lin, Erica V and Arce, Betania and Alvarez-Arango, Santiago and Dispenza, Melanie C},
  title = {Current and future landscape of Bruton tyrosine kinase inhibitors in allergy},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  volume = {156},
  number = {3},
  pages = {568--578},
  doi = {10.1016/j.jaci.2025.05.030}
}
Kostenlos starten →